Hepatitis C Chalk Talk

2. One major consideration or health factor when choosing hepatitis C treatment.
4. A one tablet once daily hepatitis C treatment option that must be taken with food.
7. Hepatitis C treatment that cannot be taken with proton pump inhibitors.
8. First-line treatment for hepatitis A.
11. Can be transmitted via fecal-oral route.
13. All direct-acting antivirals are contraindicated with strong ________ inducers.
17. The second of two agents in Mavyret.
18. Suffix for NS5B polymerase inhibitors.
20. Treatment that can be combined with direct-acting antivirals for patients who failed prior treatment.
21. Agent unique to Vosevi.
22. Agent unique to Harvoni.
25. Suffix for NS5A replication complex inhibitors.
26. The second of two agents in Zepatier.

1. Preventable via vaccination AND risk factor modification.
3. Hepatitis C treatment that is approved for genotypes 1, 4, 5, and 6.
5. Patients taking direct-acting antivirals should be tested and monitored for HBV infection due to risk of __________.
6. Hepatitis C treatment that must be taken as 3 tablets once daily.
9. Agent contained in Epclusa, Harvoni, and Vosevi.
10. One of two agents in Mavyret.
12. Hepatitis C treatment that is the most limited in applications, and is only approved for genotypes 1 and 4.
14. A major drug interaction exists between this drug and sofosbuvir-based regimens.
15. The leading cause of liver transplants and liver cancer.
16. Suffix for NS3/4A protease inhibitors.
19. One of two agents in Zepatier.
23. Acronym for the first-line treatment for hepatitis C.
24. The term used to described undetectable HCV RNA levels 12 weeks after completing treatment